OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide...

Full description

Bibliographic Details
Main Authors: Robert C Stein, Janet A Dunn, John MS Bartlett, Amy F Campbell, Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny L Donovan, Christopher McCabe, Luke Hughes-Davies, Andreas Makris
Format: Article
Language:English
Published: NIHR Journals Library 2016-02-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta20100
id doaj-577852a5b41847748a6b9015ea7410ba
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Robert C Stein
Janet A Dunn
John MS Bartlett
Amy F Campbell
Andrea Marshall
Peter Hall
Leila Rooshenas
Adrienne Morgan
Christopher Poole
Sarah E Pinder
David A Cameron
Nigel Stallard
Jenny L Donovan
Christopher McCabe
Luke Hughes-Davies
Andreas Makris
spellingShingle Robert C Stein
Janet A Dunn
John MS Bartlett
Amy F Campbell
Andrea Marshall
Peter Hall
Leila Rooshenas
Adrienne Morgan
Christopher Poole
Sarah E Pinder
David A Cameron
Nigel Stallard
Jenny L Donovan
Christopher McCabe
Luke Hughes-Davies
Andreas Makris
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
Health Technology Assessment
author_facet Robert C Stein
Janet A Dunn
John MS Bartlett
Amy F Campbell
Andrea Marshall
Peter Hall
Leila Rooshenas
Adrienne Morgan
Christopher Poole
Sarah E Pinder
David A Cameron
Nigel Stallard
Jenny L Donovan
Christopher McCabe
Luke Hughes-Davies
Andreas Makris
author_sort Robert C Stein
title OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
title_short OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
title_full OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
title_fullStr OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
title_full_unstemmed OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
title_sort optima prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
publisher NIHR Journals Library
series Health Technology Assessment
issn 1366-5278
2046-4924
publishDate 2016-02-01
description Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS. Objectives: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of randomisation to test-driven treatment assignment compared with usual care and to select an assay for study in the main RCT. Design: Partially blinded RCT with adaptive design. Setting: Thirty-five UK hospitals. Participants: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast cancer and with 1–9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter. Interventions: Randomisation between two treatment options. Option 1 was standard care consisting of chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX® test (Genomic Health Inc., Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard care [if ‘recurrence score’ (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated chemotherapy were blind to their randomisation. Main outcome measures: The pre-specified success criteria were recruitment of 300 patients in no longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85% of patients. Results: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to 5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and recordings of potential participant consultations made as part of the integral qualitative recruitment study provided insights into recruitment barriers and led to interventions designed to improve recruitment. Patient information was changed as the result of feedback from three patient focus groups. Additional multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint®/BluePrint® (Agendia Inc., Irvine, CA, USA), Prosigna® (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4 automated quantitative immunofluorescence (AQUA®) [NexCourse BreastTM (Genoptix Inc. Carlsbad, CA, USA)] and MammaTyper® (BioNTech Diagnostics GmbH, Mainz, Germany) categorised comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33–0.60 and 0.39–0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the value of information to the NHS from further research into multiparameter testing is high irrespective of the test evaluated. Prosigna is currently the highest priority for further study. Conclusions: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS. Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive HER2-negative early breast would be appropriate to take place in the NHS. Trial registration: Current Controlled Trials ISRCTN42400492. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10. See the NIHR Journals Library website for further project information. The Government of Ontario funded research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from the NIHR University College London Hospitals Biomedical Research Centre.
url https://doi.org/10.3310/hta20100
work_keys_str_mv AT robertcstein optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT janetadunn optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT johnmsbartlett optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT amyfcampbell optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT andreamarshall optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT peterhall optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT leilarooshenas optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT adriennemorgan optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT christopherpoole optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT sarahepinder optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT davidacameron optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT nigelstallard optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT jennyldonovan optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT christophermccabe optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT lukehughesdavies optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
AT andreasmakris optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer
_version_ 1726010742480568320
spelling doaj-577852a5b41847748a6b9015ea7410ba2020-11-24T21:18:01ZengNIHR Journals LibraryHealth Technology Assessment1366-52782046-49242016-02-01201010.3310/hta2010010/34/01OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein0Janet A Dunn1John MS Bartlett2Amy F Campbell3Andrea Marshall4Peter Hall5Leila Rooshenas6Adrienne Morgan7Christopher Poole8Sarah E Pinder9David A Cameron10Nigel Stallard11Jenny L Donovan12Christopher McCabe13Luke Hughes-Davies14Andreas Makris15Department of Oncology, University College London Hospitals, London, UKWarwick Medical School, University of Warwick, Coventry, UKOntario Institute for Cancer Research, Toronto, ON, CanadaWarwick Medical School, University of Warwick, Coventry, UKWarwick Medical School, University of Warwick, Coventry, UKAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UKSchool of Social and Community Medicine, University of Bristol, Bristol, UKIndependent Cancer Patients’ Voice, London, UKWarwick Medical School, University of Warwick, Coventry, UKResearch Oncology, Division of Cancer Studies, King’s College London, London, UKEdinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UKWarwick Medical School, University of Warwick, Coventry, UKSchool of Social and Community Medicine, University of Bristol, Bristol, UKDepartment of Emergency Medicine, University of Alberta, Edmonton, AB, CanadaOncology Centre, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundations Trust, Cambridge, UKDepartment of Clinical Oncology, Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, UKBackground: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS. Objectives: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of randomisation to test-driven treatment assignment compared with usual care and to select an assay for study in the main RCT. Design: Partially blinded RCT with adaptive design. Setting: Thirty-five UK hospitals. Participants: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast cancer and with 1–9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter. Interventions: Randomisation between two treatment options. Option 1 was standard care consisting of chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX® test (Genomic Health Inc., Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard care [if ‘recurrence score’ (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated chemotherapy were blind to their randomisation. Main outcome measures: The pre-specified success criteria were recruitment of 300 patients in no longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85% of patients. Results: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to 5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and recordings of potential participant consultations made as part of the integral qualitative recruitment study provided insights into recruitment barriers and led to interventions designed to improve recruitment. Patient information was changed as the result of feedback from three patient focus groups. Additional multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint®/BluePrint® (Agendia Inc., Irvine, CA, USA), Prosigna® (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4 automated quantitative immunofluorescence (AQUA®) [NexCourse BreastTM (Genoptix Inc. Carlsbad, CA, USA)] and MammaTyper® (BioNTech Diagnostics GmbH, Mainz, Germany) categorised comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33–0.60 and 0.39–0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the value of information to the NHS from further research into multiparameter testing is high irrespective of the test evaluated. Prosigna is currently the highest priority for further study. Conclusions: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS. Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive HER2-negative early breast would be appropriate to take place in the NHS. Trial registration: Current Controlled Trials ISRCTN42400492. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10. See the NIHR Journals Library website for further project information. The Government of Ontario funded research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from the NIHR University College London Hospitals Biomedical Research Centre.https://doi.org/10.3310/hta20100